Christian Heidbreder

Christian Heidbreder

Chief Scientific Officer

Christian combines 30 years leadership experience in the neurosciences spanning the academic, governmental, and industrial sectors across Europe and the US. During his career, Christian has published over 350 peer-reviewed scientific publications, reviews, book chapters, and published conference proceedings.

Christian began his career as a researcher at the University of Louvain in Belgium, at the National Institute on Drug Abuse in Baltimore, at Princeton University, and at the Swiss Federal Institute of Technology in Zürich. Christian subsequently held positions of increasing responsibility at SmithKline-Beecham’s Neuroscience Department in Harlow (UK), GSK’s R&D Centre of Excellence for Drug Discovery in Psychiatry in Verona (Italy), and Altria Client Services’ Health Sciences Department in Richmond, Virginia.

Christian was appointed Global R&D Director at RBP in 2009 with a remit to lead global strategies (including Strategic Portfolio Management, Preclinical and Clinical Development, Chemistry, Manufacturing & Controls, and Regulatory Affairs) to drive the development of new pharmacotherapies in the area of addiction and related co-morbidities.

Christian holds BA, MA, and PhD degrees from the University of Louvain and a Certificate in Strategic Innovation from the Wharton Business School. He is an Affiliate Professor in the Department of Pharmacology & Toxicology of the Virginia Commonwealth University School of Medicine since 2010. He is also a Governance Fellow of the National Association of Corporate Directors (NACD) since 2014. In 2018, Christian was appointed by Alex M. Azar II, Secretary of Health and Human Services (HHS), to serve as a member of the National Advisory Council on Drug Abuse (NACDA). The same year Christian was also appointed by Dr. Francis Collins, Director of the National Institutes of Health (NIH), to the Helping to End Addiction Long-term (HEAL) Multi-Disciplinary Working Group (MDWG) focused on a federal effort to speed scientific solutions to stem the opioid crisis.

.